{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,16]],"date-time":"2026-11-16T17:21:32Z","timestamp":1794849692776,"version":"4.9.1"},"reference-count":54,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007273","name":"Weill Cornell Medical College","doi-asserted-by":"publisher","award":["1-UL1-TR002384-01"],"award-info":[{"award-number":["1-UL1-TR002384-01"]}],"id":[{"id":"10.13039\/100007273","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cghjournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Gastroenterology and Hepatology"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1016\/j.cgh.2021.03.034","type":"journal-article","created":{"date-parts":[[2021,3,31]],"date-time":"2021-03-31T13:47:06Z","timestamp":1617198426000},"page":"e361-e379","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":192,"title":["Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5587-7964","authenticated-orcid":false,"given":"Waseem","family":"Ahmed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Galati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul J.","family":"Christos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy","family":"Longman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana J.","family":"Lukin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ellen","family":"Scherl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Battat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cgh.2021.03.034_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/ajg.2018.27","article-title":"ACG Clinical Guideline: Management of Crohn's Disease in Adults","volume":"113","author":"Lichtenstein","year":"2018","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib2","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1053\/j.gastro.2020.01.007","article-title":"AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis","volume":"158","author":"Singh","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.034_bib3","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1111\/j.1365-2036.2011.04599.x","article-title":"Review article: remission rates achievable by current therapies for inflammatory bowel disease","volume":"33","author":"Peyrin-Biroulet","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.03.034_bib4","first-page":"S13","article-title":"SONIC study: a randomized, double-blind trial comparing infliximab and infliximab plus azathioprine to azathioprine in patients with Crohn's disease na\u00efve to immunomodulators and biologic therapy","volume":"15","author":"Sandborn","year":"2009","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.03.034_bib5","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/S1542-3565(04)00344-1","article-title":"Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety","volume":"2","author":"Dubinsky","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.034_bib6","article-title":"Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2\/3 studies","author":"Sandborn","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.03.034_bib7","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.cgh.2021.03.034_bib8","first-page":"549","article-title":"Combining biologic agents in inflammatory bowel disease","volume":"15","author":"Abreu","year":"2019","journal-title":"Gastroenterol Hepatol (N Y)"},{"key":"10.1016\/j.cgh.2021.03.034_bib9","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1002\/ibd.20014","article-title":"Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab","volume":"13","author":"Sands","year":"2007","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.03.034_bib10","doi-asserted-by":"crossref","first-page":"427","DOI":"10.7326\/0003-4819-144-6-200603210-00010","article-title":"Evaluation of the quality of prognosis studies in systematic reviews","volume":"144","author":"Hayden","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2021.03.034_bib11","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cgh.2021.03.034_bib12","doi-asserted-by":"crossref","first-page":"S823","DOI":"10.14309\/00000434-201610001-01725","article-title":"Combination of biologic agents in the management of severe refractory Crohn\u2019s disease: a case report of concomitant treatment with vedolizumab and adalimumab","volume":"111","author":"Afzali","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib13","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.14309\/01.ajg.0000613016.81984.79","article-title":"Successful use of combination biologic therapy in medically refractory pediatric Crohn's disease and sacroiliitis","volume":"114","author":"Bass","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2016-000127","article-title":"Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis","volume":"4","author":"Bethge","year":"2017","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib15","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1097\/MEG.0000000000001919","article-title":"Landmarks for dual biological therapy in inflammatory bowel disease: lesson from two case reports of vedolizumab in combination with ustekinumab","volume":"32","author":"Biscaglia","year":"2020","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.034_bib16","doi-asserted-by":"crossref","first-page":"S341","DOI":"10.1093\/ecco-jcc\/jjx002.638","article-title":"Combination treatment with vedolizumab and anti-TNF-\u03b1 in inflammatory bowel disease: safety data","volume":"11","author":"Buer","year":"2017","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.03.034_bib17","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1093\/ibd\/izx110","article-title":"Combining anti-TNF-alpha and vedolizumab in the treatment of inflammatory bowel disease: a case series","volume":"24","author":"Buer","year":"2018","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.03.034_bib18","doi-asserted-by":"crossref","first-page":"S-1208","DOI":"10.1016\/S0016-5085(20)33683-0","article-title":"Tofacitinib is safe and effective as monotherapy or in combination with biologic therapy in patients with Crohn's disease","volume":"158","author":"Clark-Snustad","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.034_bib19","doi-asserted-by":"crossref","DOI":"10.5070\/D3259045519","article-title":"Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab","volume":"25","author":"Cline","year":"2019","journal-title":"Dermatol Online J"},{"key":"10.1016\/j.cgh.2021.03.034_bib20","article-title":"Dual biologic and small molecule therapy for the treatment of refractory pediatric inflammatory bowel disease","author":"Dolinger","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.03.034_bib21","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1093\/ibd\/izaa092","article-title":"Double biologic therapy for refractory stricturing Crohn's disease: a successful case of deep remission with ustekinumab and vedolizumab","volume":"26","author":"Elmoursi","year":"2020","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.03.034_bib22","first-page":"1021","article-title":"Combining biologics in inflammatory bowel disease: is it useful?","volume":"25","author":"Filippi","year":"2018","journal-title":"Hepato-Gastro Oncol Dig"},{"key":"10.1016\/j.cgh.2021.03.034_bib23","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1038\/ajg.2017.242","article-title":"Long-term combination therapy with anti-TNF plus vedolizumab induces and maintains remission in therapy-refractory Ulcerative colitis","volume":"112","author":"Fischer","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib24","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1111\/apt.15891","article-title":"Letter: combination of biologics in inflammatory bowel diseases","volume":"52","author":"Fumery","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.03.034_bib25","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/1751-2980.12867","article-title":"The use of combination biological or small molecule therapy in inflammatory bowel disease: a retrospective cohort study","volume":"21","author":"Glassner","year":"2020","journal-title":"Journal of Digestive Diseases"},{"key":"10.1016\/j.cgh.2021.03.034_bib26","doi-asserted-by":"crossref","first-page":"S355","DOI":"10.14309\/01.ajg.0000704876.81549.14","article-title":"S707 - The use of combination vedolizumab and ustekinumab in Crohn\u2019s disease: a retrospective cohort study","volume":"115","author":"Glassner","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib27","doi-asserted-by":"crossref","first-page":"S440","DOI":"10.1093\/ecco-jcc\/jjz203.637","article-title":"Safety and efficacy of combining biological therapies together or with small molecules in patients with inflammatory bowel disease: A retrospective multicentre national observational case series study","volume":"14","author":"Goessens","year":"2020","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.03.034_bib28","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1053\/j.gastro.2019.11.275","article-title":"Safety and efficacy of combining biologicals in children with inflammatory bowel disease","volume":"158","author":"Goyal","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.034_bib29","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1038\/ajg.2015.355","article-title":"Vedolizumab and infliximab combination therapy in the treatment of Crohn's disease","volume":"110","author":"Hirten","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib30","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1016\/j.cgh.2018.02.024","article-title":"Combining biologics in inflammatory bowel disease and other immune mediated inflammatory disorders","volume":"16","author":"Hirten","year":"2018","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.034_bib31","doi-asserted-by":"crossref","first-page":"E49","DOI":"10.1097\/MIB.0000000000001232","article-title":"Efficacy of combination vedolizumab and ustekinumab for refractory Crohn's disease","volume":"23","author":"Huff-Hardy","year":"2017","journal-title":"Inflamm Bowel Dis"},{"key":"10.1016\/j.cgh.2021.03.034_bib32","doi-asserted-by":"crossref","first-page":"S1090","DOI":"10.14309\/00000434-201710001-01972","article-title":"Combination ustekinumab and vedolizumab for vulvar and Crohn's colitis highlights the advantages and limitations of systemic and mucosal specific biologic therapy","volume":"112","author":"Kim","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib33","doi-asserted-by":"crossref","first-page":"S360","DOI":"10.14309\/00000434-201710001-00649","article-title":"Combination of 2 biologics and\/or small molecules in management of inflammatory bowel disease","volume":"112","author":"Koduru","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib34","doi-asserted-by":"crossref","first-page":"S357","DOI":"10.1093\/ecco-jcc\/jjx002.668","article-title":"Combination therapy of vedolizumab and a TNF antagonist in IBD patients with severe chronic active, therapy refractory disease course","volume":"11","author":"Kuehbacher","year":"2017","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.03.034_bib35","doi-asserted-by":"crossref","first-page":"S-881","DOI":"10.1016\/S0016-5085(19)39173-5","article-title":"Combination therapy of vedolizumab and tofacitinib in IBD Patients with chronic active refractory disease course and spondylarthritis","volume":"156","author":"Kuehbacher","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cgh.2021.03.034_bib36","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2020.02.017","article-title":"Combination biologic therapy in inflammatory bowel disease: experience from a tertiary care center","volume":"19","author":"Kwapisz","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.034_bib37","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.cgh.2018.08.017","article-title":"Combination therapy with vedolizumab and tofacitinib in a patient with ulcerative colitis and spondyloarthropathy","volume":"17","author":"Le Berre","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cgh.2021.03.034_bib38","doi-asserted-by":"crossref","first-page":"S1143","DOI":"10.14309\/01.ajg.0000597696.98363.85","article-title":"Successful treatment of ulcerative colitis and seronegative inflammatory spondyloarthritis using concomitant vedolizumab and tofacitinib: a case report","volume":"114","author":"Lee","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib39","doi-asserted-by":"crossref","first-page":"5264216","DOI":"10.1155\/2017\/5264216","article-title":"Ustekinumab and vedolizumab dual biologic therapy in the treatment of Crohn's disease","volume":"2017","author":"Liu","year":"2017","journal-title":"Case Report Med"},{"key":"10.1016\/j.cgh.2021.03.034_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2018-000243","article-title":"Safety of dual biological therapy in Crohn's disease: A case series of vedolizumab in combination with other biologics","volume":"5","author":"Mao","year":"2018","journal-title":"BMJ Open Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib41","first-page":"579","article-title":"Combining biological agents in severe paediatric inflammatory bowel disease, an experience of fourteen cases","volume":"68","author":"Olbj\u00f8rn","year":"2019","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2021.03.034_bib42","first-page":"331","article-title":"Combination of 2 biologicals in pediatric Crohn's disease with paradoxical psoriasis due to TNF alfa inhibitors","volume":"62","author":"Olbj\u00f8rn","year":"2016","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"key":"10.1016\/j.cgh.2021.03.034_bib43","first-page":"S311","article-title":"Paediatric Crohn's disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab","volume":"10","author":"Olbj\u00f8rn","year":"2016","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.03.034_bib44","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s40272-020-00396-1","article-title":"Combination of biological agents in moderate to severe pediatric inflammatory bowel disease: a case series and review of the literature","volume":"22","author":"Olbj\u00f8rn","year":"2020","journal-title":"Pediatr Drugs"},{"key":"10.1016\/j.cgh.2021.03.034_bib45","doi-asserted-by":"crossref","first-page":"S480","DOI":"10.1093\/ecco-jcc\/jjy222.841","article-title":"The use of combination biologic therapy in inflammatory bowel disease: a single tertiary centre experience","volume":"13","author":"Panaccione","year":"2019","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.03.034_bib46","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1093\/ecco-jcc\/jjaa149","article-title":"Dual targeted therapy: a possible option for the management of refractory inflammatory bowel disease","volume":"15","author":"Privitera","year":"2021","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.03.034_bib47","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1080\/00365521.2019.1597159","article-title":"Dual biological therapy with anti-TNF, vedolizumab or ustekinumab in inflammatory bowel disease: a systematic review with pool analysis","volume":"54","author":"Ribaldone","year":"2019","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib48","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1136\/annrheumdis-2017-212819","article-title":"Simultaneous inhibition of alpha4\/beta7 integrin and tumour necrosis factor-alpha in concomitant spondyloarthritis and inflammatory bowel disease","volume":"77","author":"Richard","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.cgh.2021.03.034_bib49","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1093\/ecco-jcc\/jjx142","article-title":"Co-treatment with golimumab and vedolizumab to treat severe UC and associated spondyloarthropathy","volume":"12","author":"Roblin","year":"2018","journal-title":"J\u00a0Crohn\u2019s Colitis"},{"key":"10.1016\/j.cgh.2021.03.034_bib50","doi-asserted-by":"crossref","first-page":"S1098","DOI":"10.14309\/00000434-201710001-01988","article-title":"Use of tofacitinib for the treatment of arthritis associated with vedolizumab in ulcerative colitis","volume":"112","author":"Rubin","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib51","doi-asserted-by":"crossref","first-page":"103","DOI":"10.4292\/wjgpt.v8.i2.103","article-title":"Combination therapy for inflammatory bowel disease","volume":"8","author":"Sultan","year":"2017","journal-title":"World J Gastrointest Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.03.034_bib52","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1111\/apt.15719","article-title":"Efficacy and safety of simultaneous treatment with two biologic medications in refractory Crohn\u2019s disease","volume":"51","author":"Yang","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cgh.2021.03.034_bib53","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1038\/ajg.2016.66","article-title":"Ustekinumab and anti-TNF combination therapy in patients with inflammatory bowel disease","volume":"111","author":"Yzet","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cgh.2021.03.034_bib54","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/ibd\/izx072","article-title":"Infliximab for Crohn's disease: more than 13 years of real-world experience","volume":"24","author":"Lichtenstein","year":"2018","journal-title":"Inflamm Bowel Dis"}],"container-title":["Clinical Gastroenterology and Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652100344X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S154235652100344X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:36:20Z","timestamp":1761543380000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S154235652100344X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3]]},"references-count":54,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["S154235652100344X"],"URL":"https:\/\/doi.org\/10.1016\/j.cgh.2021.03.034","relation":{},"ISSN":["1542-3565"],"issn-type":[{"value":"1542-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Gastroenterology and Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cgh.2021.03.034","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 by the AGA Institute","name":"copyright","label":"Copyright"}]}}